^
    7ms
    A Study of ERAS-601 in People With Chordoma (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    ERAS-601
    10ms
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Erasca, Inc. | Trial completion date: Jul 2025 --> Feb 2026 | Trial primary completion date: May 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    over1year
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Erasca, Inc. | Trial completion date: May 2024 --> Jul 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    over1year
    HERKULES-1: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Active, not recruiting, Erasca, Inc. | Phase classification: P1b/2 --> P1/2 | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: May 2024 --> May 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ERAS-007 • ERAS-601
    2years
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=200, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    over2years
    HERKULES-2: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (clinicaltrials.gov)
    P1b, N=24, Completed, Erasca, Inc. | Active, not recruiting --> Completed | N=200 --> 24 | Trial completion date: Mar 2024 --> Apr 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • KRAS G12C
    |
    Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
    over2years
    HERKULES-1: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b/2, N=200, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    ERAS-007 • ERAS-601
    almost3years
    HERKULES-2: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (clinicaltrials.gov)
    P1b, N=200, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1b
    Enrollment closed • Phase classification • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • KRAS G12C
    |
    Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
    over3years
    HERKULES-4: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1b/2, N=0, Withdrawn, Erasca, Inc. | N=120 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Xospata (gilteritinib) • ERAS-007 • ERAS-601
    almost4years
    ERAS-601, a potent inhibitor of SHP2, synergistically enhances the activity of a FLT3 inhibitor, gilteritinib, in FLT3-mutated AML tumor models (AACR 2022)
    The combination of ERAS-601 with gilteritinib achieves a more durable tumor growth inhibition than the respective gilteritinib and ERAS-601 monotherapies in vivo. These preclinical data support the clinical development of ERAS-601 in combination with gilteritinib in FLT3-altered AML.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    FLT3 mutation
    |
    Xospata (gilteritinib) • ERAS-601
    almost4years
    ERAS-601, a potent allosteric inhibitor of SHP2, demonstrates anti-tumor activity in RAS/MAPK-driven tumor models (AACR 2022)
    ERAS-601 also inhibits tumor growth in multiple RAS/MAPK-driven CDX and PDX models that harbor EGFR, KRAS, BRAF Class III, and NF1LOF mutations. ERAS-601 is a potent and selective allosteric SHP2 inhibitor that demonstrates anti-tumor activity in vitro and in vivo and is currently being studied as a monotherapy in an ongoing Phase 1 clinical study in patients with advanced or metastatic solid tumors (FLAGSHP-1, NCT04670679).
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • DUSP6 (Dual specificity phosphatase 6)
    |
    EGFR mutation • BRAF mutation • NF1 mutation
    |
    ERAS-601
    almost4years
    ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the efficacy of sotorasib/adagrasib and cetuximab in NSCLC, CRC, and HNSCC tumor models (AACR 2022)
    These nonclinical data support the clinical development of ERAS-601 in combination with a KRASG12C inhibitor in NSCLC and CRC tumors, and ERAS-601 in combination with cetuximab in RAS/RAF wild type CRC as well as HPV-negative HNSCC tumors. Both combinations are being studied in ongoing clinical studies (HERKULES-2, NCT04959981; FLAGSHP-1, NCT04670679).
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    KRAS mutation • EGFR amplification
    |
    Erbitux (cetuximab) • Lumakras (sotorasib) • Krazati (adagrasib) • ERAS-601